Zymeworks Stock Price, News & Analysis

Zymeworks (Nasdaq: ZYME) outlined strategic priorities for 2026, highlighting positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2+ gastroesophageal adenocarcinoma and a planned supplemental BLA submission in 1H-2026. Key financials: potential regulatory milestones of $440.0M (US $250M, EU $100M, Japan $75M, China $15M), cash and marketable securities of approximately $270.6M as of Dec 31, 2025, and a $125.0M authorized share repurchase program (≈$19.0M used to date). Guidance includes ~$300.0M of adjusted gross operating expense (non-GAAP) over 2026–2028 and an expectation that cash plus anticipated milestones could fund operations beyond 2028.

Zymeworks (Nasdaq: ZYME) reported positive Phase 3 HERIZON-GEA-01 results: Ziihera (zanidatamab-hrii) plus chemotherapy, with or without tislelizumab, showed ~35% reduction in PFS risk versus trastuzumab plus chemotherapy and a median PFS of 12.4 months vs 8.1 months for control. The Ziihera+tislelizumab arm achieved a median OS of 26.4 months (a >7-month improvement; HR 0.72, P=0.0043), the longest reported in a Phase 3 GEA trial. Safety was consistent with HER2 and immunotherapy effects; higher Grade ≥3 TRAE rates were observed on the triple arm. Results will be presented at ASCO GI on Jan 8, 2026. Zymeworks is eligible for up to $440.0 million in GEA regulatory milestones.

Zymeworks (NASDAQ: ZYME) announced participation in upcoming investor and medical conferences in January 2026, including the ASCO Gastrointestinal Cancers Symposium (Jan 8–10, 2026) in San Francisco and the J.P. Morgan Annual Healthcare Conference (Jan 12–16, 2026).

At ASCO GI, Zymeworks will present a Trials-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma (Abstract TPS608) on Jan 9, 11:30 am–1:00 pm PT. A partner presentation will feature late-breaking data for HERIZON-GEA-01 (zanidatamab combinations) on Jan 8 (LBA285).

Management will hold a corporate presentation and one-on-one meetings at J.P. Morgan, with the corporate presentation scheduled for Jan 14, 2026 at 3:00 pm PT. Abstract release timings are Jan 5 at 2:00 pm PT (most abstracts) and late-breaking abstracts at presentation day 7:00 am PT.

Zymeworks (Nasdaq: ZYME) announced management will attend two investor conferences in Miami in early December 2025.

Management will take part in one-on-one meetings and a fireside chat at the Evercore 8th Annual Healthcare Conference on Dec 2, 2025 at 10:00 AM ET, and at the Citi 2025 Global Healthcare Conference on Dec 3, 2025 at 3:15 PM ET.

Zymeworks (Nasdaq: ZYME) appointed Scott Platshon as Acting Chief Investment Officer effective Nov 18, 2025. Platshon will report to CEO Kenneth Galbraith and manage expected future cash flows from Ziihera (zanidatamab-hrii) and other licensed assets, and lead the operational execution of the company’s healthcare asset aggregation strategy.

Platshon stepped down from Zymeworks' board and will serve part-time while continuing as a Partner at EcoR1 Capital. The role focuses on converting royalty and asset cash flows into a diversified, revenue-generating portfolio to support long-term shareholder returns.

Zymeworks (NASDAQ: ZYME) announced a strategic initiative to optimize value from licensed products by building a diversified portfolio of revenue-generating healthcare assets while retaining in-house R&D capabilities.

Key elements: potential near-term Ziihera GEA regulatory milestones of $440.0M, pasritamig milestones of $434.0M plus royalties, a new $125.0M share repurchase authorization, and reported cash, cash equivalents and investments of $299.4M as of Sept 30, 2025.

Zymeworks (Nasdaq: ZYME) reported positive topline Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).

Key findings: Ziihera plus chemotherapy showed a clinically meaningful, statistically significant improvement in PFS versus trastuzumab plus chemotherapy and a clinically meaningful effect with a strong trend toward significance for OS at the first interim; Ziihera+Tevimbra (tislelizumab)+chemotherapy showed statistically significant improvements in OS and PFS. Safety was consistent with known profiles and no new signals were observed.

Next steps: Jazz plans a supplemental BLA submission in 1H 2026 and will present data in Q1 2026.

Zymeworks (NASDAQ: ZYME) reported 3Q-2025 results and a corporate update on Nov 6, 2025. Key highlights: revenue $27.6M (up from $16.0M in 3Q-2024) including a $25.0M J&J milestone and $1.0M royalties; net loss $19.6M vs $29.9M year-ago; cash resources $299.4M as of Sept 30, 2025 with projected runway into 2H-2027 when combined with anticipated regulatory milestones.

Clinical progress: encouraging Phase 1 ZW191 data presented (ORR 53% overall, 64% in gynecological cancers at 6.4–9.6 mg/kg); dose-optimization in ovarian cancer expected to start in 4Q-2025; first patient dosed in ZW251 Phase 1 for hepatocellular carcinoma. Completed $22.7M of share repurchases to Nov 4, 2025.

Zymeworks (Nasdaq: ZYME) announced that management will participate in investor conferences in November 2025. Key appearances include one-on-one meetings at the Stifel Healthcare Conference on November 11, 2025 in New York, and one-on-one meetings at the Jefferies London Healthcare Conference on November 17–19, 2025 in London.

The company is a clinical-stage biotechnology firm developing multifunctional biotherapeutics for oncology, inflammation, and autoimmune diseases; these investor meetings are opportunities to discuss clinical progress and corporate strategy with investors and analysts.